Companies › Berlin-Chemie AG Menarini Group
2 active drug programs in 16 registered trials: 6 Phase 1, 5 Phase 4, 3 Phase 3, 2 Phase 2; Other, Genitourinary, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tamsulosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis … | – |
| Torasemide tablet 10 mg Loop diuretic - inhibits Na-K-2Cl cotransporter | SLC12A2 | Phase 1 | Healthy Adult Male and Female Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07091669 | Tamsulosin | Phase 1 | Healthy Volunteers | Other | Aug 2025 |
| NCT07146711 | Tamsulosin | Phase 1 | Healthy Adult Males Volunteers | Other | Oct 2025 |
| NCT07201584 | Torasemide tablet 10 mg | Phase 1 | Healthy Adult Male and Female Volunteers | Other | Dec 2025 |
| NCT07124299 | Tamsulosin | Phase 4 | Nephrolithiasis | Genitourinary | Jan 2026 |
| NCT06843538 | Tamsulosin | Phase 3 | Postoperative Urinary Retention (POUR) | Other | Feb 2026 |
| NCT07156916 | Tamsulosin | Phase 1 | Healthy Volunteer Male Subjects | Other | Mar 2026 |
| NCT04147806 | Tamsulosin | Phase 1 | Prostate Cancer | Oncology | Jul 2026 |
| NCT06737016 | Tamsulosin | Phase 3 | Posterior Urethral Valve | Other | Nov 2026 |
| NCT04597372 | Tamsulosin | Phase 2 | Urinary Retention Postoperative | Other | Dec 2026 |
| NCT06001619 | Tamsulosin | Phase 4 | Prostatic Hyperplasia | Oncology | Dec 2026 |
| NCT07815379 | Tamsulosin | Phase 4 | BPH (Benign Prostatic Hyperplasia) | Genitourinary | Jan 2027 |
| NCT03609580 | Tamsulosin | Phase 1 | Urinary Retention | Oncology | Mar 2027 |
| NCT07623876 | Tamsulosin | Phase 2 | Renal Stones | Genitourinary | Apr 2027 |
| NCT07650968 | Tamsulosin | Phase 4 | Acute Urinary Retention | Genitourinary | May 2027 |
| NCT06966804 | Tamsulosin | Phase 3 | Stent Related Symptoms | Other | May 2027 |
| NCT07310797 | Tamsulosin | Phase 4 | Ureteral Calculi | Genitourinary | Dec 2029 |
Santen SAS Opus Genetics Applied Biology ARS Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.